Nurix Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $2.90B
- P/E (TTM)
- 10.8
- Dividend yield
- 0.00%
Earnings
Next report expected Jan 27, 2027, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q3 FY2026 Ended Aug 31, 2026 | Oct 13, 2026 | Before market open | $673.10M | $4.73 | – |
| Q2 FY2026 Ended May 31, 2026 | Jul 9, 2026 | After market close | $9.00M | – | – |
| Q1 FY2026 Ended Feb 28, 2026 | Apr 8, 2026 | Before market open | $6.30M | – | – |
| Q4 FY2025 Ended Nov 30, 2025 | Jan 28, 2026 | After market close | $13.60M | $-0.82 | – |
| Q3 FY2025 Ended Aug 31, 2025 | Oct 9, 2025 | After market close | $7.90M | $-1.03 | – |
| Q2 FY2025 Ended May 31, 2025 | Jul 9, 2025 | After market close | $44.10M | $-0.52 | – |
| Q1 FY2025 Ended Feb 28, 2025 | Apr 8, 2025 | After market close | $18.50M | $-0.67 | – |
| Q4 FY2024 Ended Nov 30, 2024 | Jan 28, 2025 | After market close | $13.30M | $-0.75 | – |
| Q3 FY2024 Ended Aug 31, 2024 | Oct 11, 2024 | After market close | – | – | – |
| Q2 FY2024 Ended May 31, 2024 | Jul 11, 2024 | After market close | – | – | – |
| Q1 FY2024 Ended Feb 29, 2024 | Apr 10, 2024 | Before market open | – | – | – |
Press releases
Announcements Nurix Therapeutics filed with the SEC
Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Nurix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Nurix Therapeutics to Report Updated Phase 1a/b Results for BTK Degrader Bexobrutideg, Highlighting Durable Responses in Relapsed/Refractory CLL/SLL and Promising Activity in Earlier Lines of Therapy
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Nurix Therapeutics Announces Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Unlocking the Full Potential of Bexobrutideg A Global Collaboration Between Nurix and Roche June 8, 2026 Exhibit 99.2
Material agreement · Regulation FD disclosure · EX-99.2 to Form 8-K
Nurix Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
Results of operations · EX-99.1 to Form 8-K
Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides a Corporate Update
Results of operations · EX-99.1 to Form 8-K
Protein Degraders to Outmatch Cancer and Autoimmune Disease J.P. Morgan Healthcare Conference January 12, 2026 Exhibit 99.1
Regulation FD disclosure · EX-99.1 to Form 8-K
Nurix Therapeutics Outlines 2026 Goals and Objectives for Advancing Bexobrutideg and Its Pipeline of Novel Degrader-Based Medicines in Cancer and Autoimmune Diseases
Regulation FD disclosure · EX-99.2 to Form 8-K
Nurix Therapeutics Presents New Data Demonstrating Durable, Deepening Responses in Phase 1 Trial of Bexobrutideg (NX-5948) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Nurix Therapeutics Presents New Data from the Phase 1 Trial of Bexobrutideg (NX-5948) in Waldenström Macroglobulinemia at the 67 th American Society of Hematology (ASH) Annual Meeting and Exposition
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Meeting the Needs of Patients with CLL and WM – Bexobrutideg Clinical Update from ASH 2025 American Society of Hematology December 8, 2025 Exhibit 99.3
Regulation FD disclosure · Other events · EX-99.3 to Form 8-K
Nurix Therapeutics Announces $250.0 Million Registered Offering of Common Stock
Other events · EX-99.1 to Form 8-K
Nurix Initiates DAYBreak™ Pivotal Study of Bexobrutideg in Relapsed or Refractory Chronic Lymphocytic Leukemia
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Bexobrutideg Investor Update Investor Presentation October 2025
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Nurix Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
Results of operations · EX-99.1 to Form 8-K
Protein Degraders to Outmatch Cancer and Autoimmune Disease Investor Presentation September 2025
Regulation FD disclosure · EX-99.1 to Form 8-K
Nurix Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
Results of operations · EX-99.1 to Form 8-K
Nurix Therapeutics Presents Updated Positive Data Demonstrating Durable, Deepening Responses in Ongoing Clinical Trial of Bexobrutideg (NX-5948) Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Waldenström Macroglobulinemia (WM)
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Meeting the Needs of Patients with CLL and WM – Bexobrutideg Clinical Update from EHA European Hematological Association Investor Event June 12, 2025
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Nurix Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update
Results of operations · EX-99.1 to Form 8-K
Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides a Corporate Update
Results of operations · EX-99.1 to Form 8-K
Nurix Therapeutics Outlines 2025 Goals and Objectives for Advancement of Its Robust Pipeline in Cancer and Autoimmune Diseases
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Medicines to Outmatch Disease Investor Presentation January 13, 2025 Exhibit 99.2
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Nurix Therapeutics Presents New Positive Data from Phase 1a/1b Clinical Trial of NX-5948 in Chronic Lymphocytic Leukemia at the 66 th American Society of Hematology Annual Meeting
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Nurix Therapeutics Blazing a New Path in Medicine American Society of Hematology Investor Event December 9, 2024 Exhibit 99.2
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Nurix Therapeutics Reports Third Quarter Fiscal 2024 Financial Results and Provides a Corporate Update
Results of operations · EX-99.1 to Form 8-K
Leader in Targeted Protein Modulation Nurix Therapeutics Blazing a New Path in Medicine Investor Presentation September 2024
Regulation FD disclosure · EX-99.1 to Form 8-K
Nurix Therapeutics Reports Second Quarter Fiscal 2024 Financial Results and Provides a Corporate Update
Results of operations · Other events · EX-99.1 to Form 8-K
Nurix Therapeutics Presents Positive Results from Ongoing Clinical Trial of
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Nurix Therapeutics NX-5948 Clinical Update European Hematology Association Congress EHA2024 June 16, 2024
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Nurix Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering
Material agreement · Other events · EX-99.1 to Form 8-K
Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate Update
Results of operations · EX-99.1 to Form 8-K
Nurix Therapeutics Announces U.S. FDA Lifts Partial Clinical Hold on
Other events · EX-99.1 to Form 8-K
Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides a Corporate Update
Results of operations · EX-99.1 to Form 8-K
Leader in Targeted Protein Modulation Nurix Therapeutics Blazing a New Path in Medicine Investor Presentation January 2024 Exhibit 99.1
Regulation FD disclosure · EX-99.1 to Form 8-K
Nurix Therapeutics Outlines 2024 Strategic Priorities with Advancement of Targeted Protein Modulation Pipeline in Cancer and Autoimmune Diseases
Regulation FD disclosure · EX-99.2 to Form 8-K
Blazing a New Path in Medicine Investor Presentation November 2023
Regulation FD disclosure · EX-99.1 to Form 8-K
Nurix Therapeutics Announces Partial Clinical Hold For NX-2127 Phase 1 Trial
Other events · EX-99.1 to Form 8-K